Aethlon Medical, Inc. (Nasdaq: AEMD), a medical device technology company focused on unmet needs in global health, today announced that it will issue financial results for its first quarter fiscal year 2021, ended June 30, 2020 , at 4:15 pm Eastern time on Tuesday , August 11, 2020. Management will host a conference call on Tuesday
| SAN DIEGO, Aug. 4, 2020 /PRNewswire/ -- Aethlon Medical, Inc., Inc. (Nasdaq: AEMD), a medical device technology company focused on unmet needs in global health, today announced that it will issue financial results for its first quarter fiscal year 2021, ended June 30, 2020, at 4:15 pm Eastern time on Tuesday, August 11, 2020. Management will host a conference call on Tuesday, August 11, 2020 at 4:30 pm eastern time to review financial results and recent corporate developments. Following management’s formal remarks, there will be a question and answer session. Interested parties can register for the conference by navigating to http://dpregister.com/10147021.
A replay of the call will be available approximately one hour after the end of the call through August 18, 2020. The replay can be accessed via Aethlon Medical’s website or by dialing 1-877-344-7529 (domestic) or 1-412-317-0088 (international) or Canada Toll Free at 1-855-669-9658. The replay conference ID number is 10147021. About Aethlon Medical, Inc. Aethlon Medical is focused on addressing unmet needs in global health. The Aethlon Hemopurifier® is a clinical-stage immunotherapeutic device designed to combat cancer and life-threatening viral infections. In cancer, the Hemopurifier® depletes the presence of circulating tumor-derived exosomes that promote immune suppression, seed the spread of metastasis and inhibit the benefit of leading cancer therapies. The Hemopurifier® is an FDA designated “Breakthrough Device” related to the treatment of individuals with advanced or metastatic cancer who are either unresponsive to or intolerant of standard of care therapy, and with cancer types in which exosomes have been shown to participate in the development or severity of the disease cancer. The Hemopurifier also holds a Breakthrough Device designation related to life-threatening viruses that are not addressed with approved therapies. Additionally, Aethlon owns 80% of Exosome Sciences, Inc., which is focused on the discovery of exosomal biomarkers to diagnose and monitor cancer and neurological disease progression. Additional information can be found online at www.AethlonMedical.com and www.ExosomeSciences.com. Company Contact: Media Contact: Investor Contact:
SOURCE Aethlon Medical, Inc. | ||||||||||||||||||||||||||||||||||
Company Codes: NASDAQ-SMALL:AEMD | ||||||||||||||||||||||||||||||||||
View original content:
